해부 병리학 검사 시장 : 검사 유형별, 검체 유형별, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Anatomic Pathology Testing Market is projected to grow by USD 75.01 billion at a CAGR of 6.60% by 2032.

Anatomic pathology testing is the foundation of tissue-based diagnosis, combining histopathology, cytopathology, immunohistochemistry, in situ hybridization, and molecular pathology to guide clinical decisions. The market is closely linked to cancer detection, tumor classification, staging, treatment selection, and post-treatment surveillance, making it essential to oncology care pathways and precision medicine.

Demand is being reinforced by the rising global cancer burden, expanded biopsy utilization, companion diagnostic requirements, and broader adoption of digital pathology. According to the International Agency for Research on Cancer, the world recorded about 20 million new cancer cases and 9.7 million cancer deaths in 2022, with cases expected to rise substantially by 2050 as populations grow and age. This creates sustained need for high-quality anatomic pathology testing, faster turnaround times, standardized reporting, and validated biomarker interpretation across hospitals, reference laboratories, and academic medical centers.

Transformative Shifts in the Anatomic Pathology Landscape

The anatomic pathology testing landscape is shifting from microscope-centric workflows toward integrated, data-rich diagnostic ecosystems. Laboratories are prioritizing automation in tissue processing, barcoding, slide scanning, image management, and laboratory information system connectivity to reduce manual variation, improve traceability, and support accreditation-ready quality management. Digital pathology adoption is also enabling remote consultation, subspecialty review, tumor board collaboration, and multi-site workload balancing.

A second major shift is the convergence of morphology with molecular and immuno-oncology testing. Pathologists increasingly interpret tissue architecture alongside biomarker results such as HER2, PD-L1, mismatch repair proteins, EGFR, ALK, ROS1, NTRK, and other therapy-linked markers. At the same time, reimbursement scrutiny, pathology workforce shortages, and stricter quality expectations are pushing laboratories to demonstrate clinical utility, analytical validity, data integrity, and operational efficiency.

Cumulative Impact of Artificial Intelligence on Pathology Testing

Artificial intelligence is creating cumulative impact across the anatomic pathology testing value chain by enhancing slide review, case triage, quality control, and quantitative biomarker assessment. Regulatory-cleared digital pathology and AI-enabled tools have expanded the evidence base for clinical implementation, particularly in tumor detection support, mitotic counting, prostate biopsy review, breast pathology, and immunohistochemistry scoring.

The strongest near-term value of AI is workflow augmentation rather than autonomous diagnosis. Human-in-the-loop models can help prioritize urgent cases, flag potential discrepancies, standardize scoring, and improve reproducibility for biomarkers such as Ki-67, HER2, ER, PR, and PD-L1. However, adoption requires local validation, bias assessment, cybersecurity controls, audit trails, data governance, and alignment with CAP, CLIA, ISO 15189, FDA, and EU IVDR expectations.

Key Regional Insights for Anatomic Pathology Testing

Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and Southeast Asian countries invest in cancer screening, tertiary hospitals, pathology workforce development, and digital health infrastructure. The region's large population base and rising noncommunicable disease burden are increasing demand for histopathology testing, cytopathology, immunohistochemistry, molecular pathology, and remote subspecialty consultation. North America remains a mature, high-value region supported by strong oncology testing volumes, CLIA-regulated laboratories, CAP accreditation, advanced companion diagnostics, integrated cancer centers, and early digital pathology adoption.

Europe is shaped by universal healthcare systems, structured cancer programs, national screening initiatives, and the EU IVDR, which is increasing compliance requirements for diagnostic assays, laboratory-developed tests, documentation, and post-market surveillance. Latin America shows growing demand in Brazil and Mexico as private diagnostic networks and oncology services expand, but access to subspecialty pathology remains uneven across public and rural healthcare settings. The Middle East is investing in advanced hospital networks, oncology centers, international accreditation, and medical tourism, particularly in GCC countries. Africa presents long-term growth potential as cancer diagnosis needs rise, although pathology capacity, trained workforce availability, specimen referral systems, and laboratory infrastructure remain critical constraints.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, rising cancer incidence, expanding private hospital investment, medical tourism, and regional digital health initiatives are supporting demand for histopathology testing, cytopathology, immunohistochemistry, and digital consultation. The GCC is advancing pathology modernization through government-backed healthcare transformation, oncology centers, tertiary hospital development, and international accreditation, strengthening demand for advanced tissue diagnostics and companion diagnostic readiness. The European Union is a major regulatory force because the IVDR raises expectations for assay performance, documentation, post-market surveillance, and laboratory-developed test justification across anatomic pathology and molecular pathology workflows.

BRICS countries represent a high-volume growth engine, combining large patient populations with expanding diagnostic infrastructure, oncology capacity, and public health investment, although access, reimbursement, workforce availability, and quality standardization vary considerably. G7 markets remain innovation leaders in digital pathology, AI validation, molecular oncology, companion diagnostics, laboratory automation, and evidence-based reimbursement models. NATO countries, with significant overlap in North America and Europe, benefit from resilient health systems, cross-border research networks, advanced laboratory quality frameworks, and strong adoption of interoperable health data standards.

Key Country Insights in Major Anatomic Pathology Markets

The United States leads in advanced anatomic pathology testing through large reference laboratories, academic cancer centers, FDA-cleared digital pathology systems, CLIA oversight, CAP-accredited workflows, and broad biomarker adoption in oncology. Canada benefits from organized cancer care, public health coverage, and accreditation-driven laboratory quality, while continuing to address regional turnaround-time and access gaps. Mexico and Brazil are expanding private diagnostic networks, oncology services, and immunohistochemistry capacity, although public-sector access, reimbursement consistency, and subspecialty pathology availability remain uneven.

In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize cancer pathway efficiency, national screening programs, digital pathology pilots, biomarker standardization, and compliance with evolving EU diagnostic regulations, while Russia maintains significant hospital-based demand despite procurement and modernization challenges. China is scaling pathology capacity across major hospitals and oncology centers, India is seeing growth from private laboratories, cancer hospitals, and molecular oncology networks, Japan emphasizes high-quality diagnostics and aging-related cancer demand, Australia supports accreditation-led pathology services and organized cancer care, and South Korea is advancing digital pathology, precision oncology, and high-throughput laboratory modernization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize end-to-end workflow modernization, including specimen tracking, automated tissue processing, digital slide scanning, LIS integration, DICOM-compatible imaging, and secure cloud or hybrid storage. Investment decisions should be tied to measurable outcomes such as turnaround time, diagnostic concordance, pathologist productivity, quality indicators, rework reduction, and tumor board efficiency.

Organizations should also build AI governance before deployment by defining validation protocols, intended use, human oversight, model monitoring, cybersecurity, and change-control processes. Strategic partnerships with oncology providers, pharmaceutical sponsors, academic centers, and payers can improve biomarker access and companion diagnostic readiness. Workforce resilience should be addressed through subspecialty networks, remote sign-out where permitted, continuing education, training programs, and standardized reporting templates aligned with recognized pathology guidelines.

Research Methodology for Evidence-Based Market Analysis

The research approach combines secondary research, structured primary insights, and analytical triangulation. Core sources include WHO and IARC cancer statistics, OECD and World Bank health indicators, FDA device databases, CMS and CLIA guidance, CAP accreditation standards, ISO 15189 quality principles, EMA and EU IVDR documentation, peer-reviewed pathology literature, public health agency publications, and regulatory databases.

Market interpretation is based on segmentation by test type, technology, application, end user, and geography without relying on market sizing or forecasting. Findings are validated through comparison of epidemiology trends, diagnostic utilization, regulatory developments, reimbursement signals, laboratory workflow evidence, quality standards, and technology adoption patterns. AI-related conclusions are limited to documented clinical, regulatory, and operational evidence to ensure data-backed, defensible insights.

Conclusion: The Future of Anatomic Pathology Testing

The anatomic pathology testing market is entering a new phase defined by cancer burden growth, precision oncology, digital pathology, and AI-assisted workflow optimization. Tissue-based diagnosis remains indispensable because treatment selection, staging, prognosis, and biomarker confirmation continue to depend on high-quality pathology interpretation.

Future leadership will favor organizations that combine clinical excellence with scalable technology, regulatory discipline, interoperability, and measurable value creation. Laboratories that modernize operations while maintaining pathologist oversight, quality assurance, validated AI use, and patient-centered reporting will be best positioned to strengthen performance across histopathology testing, cytopathology, molecular pathology, immunohistochemistry, and companion diagnostics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anatomic Pathology Testing Market, by Test Type

• 7.1. Digital Pathology
  • 7.1.1. Image Analysis Software
  • 7.1.2. Slide Scanners
• 7.2. Hematoxylin And Eosin Staining
• 7.3. Immunohistochemistry
  • 7.3.1. Monoclonal Antibody
  • 7.3.2. Polyclonal Antibody
• 7.4. Molecular Pathology
  • 7.4.1. Fluorescence In Situ Hybridization
  • 7.4.2. Next Generation Sequencing
  • 7.4.3. Polymerase Chain Reaction
• 7.5. Special Staining
  • 7.5.1. Periodic Acid-Schiff Stain
  • 7.5.2. Silver Stain
  • 7.5.3. Trichrome Stain

8. Anatomic Pathology Testing Market, by Sample Type

• 8.1. Cytology Samples
• 8.2. Frozen Sections
• 8.3. Tissue Biopsy

9. Anatomic Pathology Testing Market, by Application

• 9.1. Genetic Disorders
  • 9.1.1. Chromosomal Disorders
  • 9.1.2. Single Gene Disorders
• 9.2. Infectious Diseases
  • 9.2.1. Bacterial Infections
  • 9.2.2. Viral Infections
• 9.3. Oncology
  • 9.3.1. Breast Cancer
  • 9.3.2. Lung Cancer
  • 9.3.3. Prostate Cancer

10. Anatomic Pathology Testing Market, by End User

• 10.1. Diagnostic Laboratories
• 10.2. Hospitals
• 10.3. Research Institutes

11. Anatomic Pathology Testing Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Anatomic Pathology Testing Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Anatomic Pathology Testing Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Abcam plc
• 15.3. Agilent Technologies Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. BioGenex Laboratories Inc.
• 15.6. Bio SB Inc.
• 15.7. Danaher Corporation
• 15.8. Eurofins Scientific SE
• 15.9. F. Hoffmann-La Roche AG
• 15.10. Hamamatsu Photonics K.K.
• 15.11. Hologic Inc.
• 15.12. Indica Labs LLC
• 15.13. Koninklijke Philips N.V.
• 15.14. Laboratory Corporation of America Holdings
• 15.15. Leica Biosystems
• 15.16. Merck KGaA
• 15.17. NeoGenomics Laboratories Inc.
• 15.18. PerkinElmer Inc.
• 15.19. Qiagen N.V.
• 15.20. Quest Diagnostics Incorporated
• 15.21. Sakura Finetek USA Inc.
• 15.22. Sonic Healthcare Limited
• 15.23. Synlab Holding GmbH
• 15.24. Sysmex Corporation
• 15.25. Thermo Fisher Scientific Inc.